Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenibManabu Morimoto, Katsuaki Tanaka, Kazushi Numata et al.|Hepatology Research|2011Cited by 77
Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trialMasaaki Kondo, Katsuaki Tanaka, Manabu Morimoto et al.|BMC Cancer|2019Cited by 77
Field practice study of half‐dose sorafenib treatment on safety and efficacy for hepatocellular carcinoma: A propensity score analysisManabu Morimoto, Katsuaki Tanaka, Kazushi Numata et al.|Hepatology Research|2014Cited by 30
Prognostic factors in patients with high-risk stage II colon cancer after curative resection: a post hoc analysis of the JFMC46-1201 trialKiichi Sugimoto, Sotaro Sadahiro, Kazuhiro Sakamoto et al.|International Journal of Colorectal Disease|2023Cited by 10